Inline extracorporeal photopheresis: evaluation of cell collection efficiency.
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
28
06
2019
revised:
13
09
2019
accepted:
20
09
2019
pubmed:
5
11
2019
medline:
17
6
2020
entrez:
5
11
2019
Statut:
ppublish
Résumé
Extracorporeal photopheresis (ECP) therapy has proved to be an effective and safe treatment for graft-versus-host-disease (GvHD), an important complication after hematopoietic stem cell transplantation. In 2016, we acquired Therakos CellEx, a dedicated inline ECP device to accomplish a significant increase in ECP activity. In literature, we found few data reporting CellEx performance evaluated in terms of collection efficiency to qualify the device. Hence, we decided to collect and analyze our data in order to build a reference in terms of expected results of the procedure. Here we report our data of ECP performed using CellEx in a 12-month period focusing on collection efficiency assessment, as well as procedural and apheretic product characteristics. We collected data of patients undergoing ECP from April 2018 to March 2019 using CellEx in order to evaluate collection efficiency. Between April 2018 and March 2019 we treated 28 adult patients affected by GvHD performing 319 ECP using CellEx. CellEx mononuclear cell product was characterized by high mononuclear cell percentage and low percentage of granulocytes, resulting particularly suitable for ECP treatments. Median collection efficiency for total nucleated cells and for mononuclear cells was 31.2% and 62.3%, respectively. Collection efficiency of CellEx was comparable to that usually obtained by cell separators designed for cell collection and was comparable to that of offline systems. Our results provide a detailed performance evaluation for inline ECP system users.
Sections du résumé
BACKGROUND
Extracorporeal photopheresis (ECP) therapy has proved to be an effective and safe treatment for graft-versus-host-disease (GvHD), an important complication after hematopoietic stem cell transplantation. In 2016, we acquired Therakos CellEx, a dedicated inline ECP device to accomplish a significant increase in ECP activity. In literature, we found few data reporting CellEx performance evaluated in terms of collection efficiency to qualify the device. Hence, we decided to collect and analyze our data in order to build a reference in terms of expected results of the procedure. Here we report our data of ECP performed using CellEx in a 12-month period focusing on collection efficiency assessment, as well as procedural and apheretic product characteristics.
STUDY DESIGN AND METHODS
We collected data of patients undergoing ECP from April 2018 to March 2019 using CellEx in order to evaluate collection efficiency.
RESULTS
Between April 2018 and March 2019 we treated 28 adult patients affected by GvHD performing 319 ECP using CellEx. CellEx mononuclear cell product was characterized by high mononuclear cell percentage and low percentage of granulocytes, resulting particularly suitable for ECP treatments. Median collection efficiency for total nucleated cells and for mononuclear cells was 31.2% and 62.3%, respectively.
CONCLUSION
Collection efficiency of CellEx was comparable to that usually obtained by cell separators designed for cell collection and was comparable to that of offline systems. Our results provide a detailed performance evaluation for inline ECP system users.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3714-3720Informations de copyright
© 2019 AABB.
Références
Worel N, Lehner E, Führer H, et al. Extracorporeal photopheresis as second-line therapy for patients with acute graft-versus-host disease: does the number of cells treated matter? Transfusion 2018;58:1045-53.
Jagasia M, Arora M, Flowers ME, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012;119:296-307.
Martin PJ, Rizzo JD, Wingard JR, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2012;18:1150-63.
Schneiderman J. Extracorporeal photopheresis: cellular therapy for the treatment of acute and chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program 2017;2017:639-44.
Arai S, Arora M, Wang T, et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 2015;21:266-74.
Pascual C, González-Arias E, Pérez-Corral AM, et al. Mononuclear cell collection for extracorporeal photopheresis by using the "off-line" system: a comparative study between COBE Spectra and Spectra Optia devices. J Clin Apher 2019; 34:359-366.
Kapadia E, Wong E, Perez-Albuerne E, et al. Extracorporeal photopheresis performed on the CELLEX compared with the UVAR-XTS instrument is more efficient and better tolerated in children with steroid-refractory graft-versus-host disease. Pediatr Blood Cancer 2015;62:1485-8.
Brosig A, Hähnel V, Orsó E, et al. Technical comparison of four different extracorporeal photopheresis systems. Transfusion 2016;56:2510-9.
Hautmann AH, Wolff D, Hahn J, et al. Extracorporeal photopheresis in 62 patients with acute and chronic GVHD: results of treatment with the COBE Spectra System. Bone Marrow Transplant 2013;48:439-45.
Piccirillo N, Putzulu R, Massini G, et al. Mononuclear cell collection for extracorporeal photopheresis: concentrate characteristics for off-line UV-A irradiation procedure. J Clin Apher 2018;33:217-21.
Bueno JL, Alonso R, Gonzalez-Santillana C, et al. A paired trial comparing mononuclear cell collection in two machines for further inactivation through an inline or offline extracorporeal photopheresis procedure. Transfusion 2019;59:340-6.
Liu C, Shah K, Dynis M, et al. Linear relationship between lymphocyte counts in peripheral blood and buffy coat collected during extracorporeal photopheresis. Transfusion 2013;53:2635-43.
Liu C, Schindler E, LeRoy M, et al. Safety and collection efficiency with a lower transfusion threshold for extracorporeal photopheresis in adult patients with graft-versus-host disease. Vox Sang 2017;112:379-87.
Shah NK, Matevosyan K, Burner J, et al. Therakos: new extracorporeal photopheresis system, CELLEX, offers superior lymphomononuclear cell collection in addition to shorter treatment times and lower extracorporeal volumes over the old standard, UVAR-XTS. The American Society for Apheresis 33rd Annual Meeting. Atlanta, Georgia, 2012. J Clin Apher 2012;27:1-40.
Tran HT, Mercado GY, Hosing CM, et al. Study comparing the efficiency of UVAR-XTS system to the CELLEX system for extracorporeal photopheresis. The American Society for Apheresis 33rd Annual Meeting. Atlanta, Georgia, 2012. J Clin Apher 2012;27:1-40.
Evans JD. Straightforward statistics for the behavioral sciences. Pacific Grove, CA: Brooks/Cole Publishing; 1996.
Bisaccia E, Vonderheid EC, Geskin L. Safety of a new, single, integrated, closed photopheresis system in patients with cutaneous T-cell lymphoma. Br J Dermatol 2009;161:167-9.
Dunbar NM, Raval JS, Johnson A, et al. Extracorporeal photopheresis practice patterns: an international survey by the ASFA ECP subcommittee. J Clin Apher 2017;32:215-23.
Uygun V, Daloglu H, Karasu G, et al. Safety and outcomes of extracorporeal photopheresis with the therakos cellex system for graft-versus-host disease in pediatric patients. J Pediatr Hematol Oncol 2015;37:209-14.
Azar N, Leblond V, Ouzegdouh M, et al. A transition from using multi-step procedures to a fully integrated system for performing extracorporeal photopheresis: a comparison of costs and efficiencies. J Clin Apher 2017;32:474-8.
Whittle RM, Denney H, Chantry AD, et al. Comparison of the CELLEX and UVAR-XTS closed-system extracorporeal photopheresis devices in the treatment of chronic graft-versus-host disease. J Clin Apher 2017;32:462-73.
Rangarajan HG, Punzalan RC, Camitta BM, et al. The use of novel Therakos™ Cellex® for extracorporeal photopheresis in treatment of graft-versus-host disease in paediatric patients. Br J Haematol 2013;163:357-64.
de Waure C, Capri S, Veneziano MA, et al. Extracorporeal photopheresis for second-line treatment of chronic graft-versus-host diseases: results from a health technology assessment in Italy. Value Health 2015;18:457-66.
Yerrabothala S, Talebian L, Klinker K, et al. Extracorporeal photopheresis for graft versus host disease: identifying a clinical pathway and associated resource utilization. J Clin Apher 2018;33:310-5.
Schwartz J, Padmanabhan A, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American Society for Apheresis: the seventh special issue. J Clin Apher 2016;31:149-62.
Cline A, Jajosky R, Shikle J, et al. Comparing leukapheresis protocols for an AML patient with symptomatic leukostasis. J Clin Apher 2018;33:396-400.
Gandelman JS, Song DJ, Chen H, et al. A prospective trial of extracorporeal photopheresis for chronic graft-versus-host disease reveals significant disease response and no association with frequency of regulatory T cells. Biol Blood Marrow Transplant 2018;24:2373-80.
Perseghin P, Galimberti S, Balduzzi A, et al. Extracorporeal photochemotherapy for the treatment of chronic graft-versus-host disease: trend for a possible cell dose-related effect? Ther Apher Dial 2007;11:85-93.